Clinical Trials
193 trialsHALTAging-1
University of Nebraska
CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
Fred Hutchinson Cancer Center
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
Stanford University
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
OHSU Knight Cancer Institute
Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia
Chinese PLA General Hospital
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Fred Hutchinson Cancer Center
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Solu Therapeutics, Inc
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
University of Washington
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
University of Colorado, Denver
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
City of Hope Medical Center
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
The First Affiliated Hospital of Soochow University
Integrated Actionable Aging Assessment for Cancer Patients Pilot
University of Colorado, Denver
Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Thomas Jefferson University
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
National Cancer Institute (NCI)
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Eastern Cooperative Oncology Group
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease
Fred Hutchinson Cancer Center
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
National Cancer Institute (NCI)
Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
University of Washington
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
Virginia Commonwealth University
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
Masonic Cancer Center, University of Minnesota
Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
SCCLG-M5
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia
Eastern Cooperative Oncology Group
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Eastern Cooperative Oncology Group
AML1208
Gruppo Italiano Malattie EMatologiche dell'Adulto
Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
Roswell Park Cancer Institute
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
Case Comprehensive Cancer Center
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
Rush University Medical Center
AML Therapy With Irradiated Allogeneic Cells
Rutgers, The State University of New Jersey
Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
Rutgers, The State University of New Jersey
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
Genetics Study of Tissue Collected From Patients With Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
Safety of Romiplostim (Nplate®) Following UCBT
Masonic Cancer Center, University of Minnesota
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
Children's Oncology Group
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
Children's Oncology Group
Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)
Carbiogene Therapeutics Co. Ltd.
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
H. Lee Moffitt Cancer Center and Research Institute
Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy
Fred Hutchinson Cancer Center
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
University of Chicago
Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
Case Comprehensive Cancer Center
Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission
Fred Hutchinson Cancer Center
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
National Cancer Institute (NCI)